P163-0892
P163-0892 is a potent and selective antifungal agent against Cryptococcus species. P163-0892 is predicted to show medium BBB penetration.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 1574576-45-6
- 화학식: C19H20N2O3S
- 분자량:356.44
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Caco-2 | IC50 |
>256 μg/mL
Compound: P163-0892; R-0892
|
Cytotoxicity against human Caco-2 cells assessed as cell growth inhibition incubated for 24 hrs by CCK-8 assay
Cytotoxicity against human Caco-2 cells assessed as cell growth inhibition incubated for 24 hrs by CCK-8 assay
|
[PMID: 35922963] |
| Erythrocyte | IC50 |
>256 μg/mL
Compound: P163-0892; R-0892
|
Cytotoxicity against rabbit RBC assessed as cell growth inhibition incubated for 24 hrs by CCK-8 assay
Cytotoxicity against rabbit RBC assessed as cell growth inhibition incubated for 24 hrs by CCK-8 assay
|
[PMID: 35922963] |
| HUVEC | IC50 |
>64 μg/mL
Compound: P163-0892; R-0892
|
Cytotoxicity against human HUVEC cells assessed as inhibition on cell growth incubated for 24 hrs by CCK-8 assay
Cytotoxicity against human HUVEC cells assessed as inhibition on cell growth incubated for 24 hrs by CCK-8 assay
|
[PMID: 35922963] |
In Vitro
P163-0892 (0-32 μg/mL; 48 h) shows antifungal activity with a MIC of 0.25 μg/mL and 0.5 μg/mL against Cryptococcus neoformans and Cryptococcus gattii, respectively[1].
P163-0892 has good aqueous solubility[1].
P163-0892 has no cytotoxicity and no obvious cardiotoxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wax moth larva infected with C. neoformans H99 or C. gattii WM178[1]
-
Dosage:10 mg/kg
-
Administration:5 days
-
Result:Increased the survival rate of larvae.
-
Animal Model:Male Sprague–Dawley rats weighing 200–250 g[1]
-
Dosage:2 mg/kg or 5 mg/kg
-
Administration:Intravenous or oral administration (Pharmacokinetic Analysis)
-
Result:Pharmacokinetic Parameters of P163-0892a[1]
route dose (mg/kg) T1/2 (h) Tmax (h) AUC0-inf (h•ng/mL) Cl (mL/h/kg) MRT0-t (h) Vdss (L/kg) BA (%) iv 2 mg/kg 7.61 749 172 2.63 7.12 po 5 mg/kg 15.3 3.17 NR 3.83 NR 0.8
aAbbreviations: iv, intravenous; po, per os; T1/2, half-life elimination in hours; Tmax, time of maximal concentration in hours; AUC, area under the curve; Cl, clearance; MRT, mean residence time; Vdss, volume of distribution at the steady state; BA, bioavailability; NR, not reportable; n = 3.
Chemical Information
-
CAS No. 1574576-45-6
-
분자량 356.44
-
화학식 C19H20N2O3S
-
SMILES
O=C(C1=C(O)C2=C(C=CS2)N(CC3=CC=CC=C3)C1=O)NCCCC
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)